Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ocular Gene Therapy Sees The Light

This article was originally published in Start Up

Executive Summary

Recent scientific advances and some initial biotech successes have spurred investors to look again at gene therapy, a space once given up for dead. Gene therapies seem particularly apt for ocular diseases, but the pathway to approval remains largely uncharted for young companies such as the four we profile in this issue: Avalanche Biotechnologies, Eyevensys, GenSight Biologics, and Hemera Biosciences.

Advertisement

Related Content

Deals of the Week Takes Stock In M&A
Third Rock Takes On Parkinson's, Gene Therapy's Next Frontier
Juno Launches With Competing Immunotherapy Programs
Hemera Biosciences Inc.
GenSight Biologics Inc.
Eyevensys SA
Avalanche Biotechnologies Inc.
uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy
Cellular And Gene Therapy Trial Design: Draft Guidance Highlights Risks
Gene Therapy Firm AMT Forced To Go Private, Backed By Forbion

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC092492

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel